Floatz logo

DEXAMETHASONE

Recurrent Lymphoplasmacytic Lymphoma

Yazeed SawalhaSmall moleculePhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Recurrent Lymphoplasmacytic Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Epirubicin
Celldex Therapeutics
Phase 2B
Ibrutinib
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Celldex Therapeutics
Phase 2B
cc-5013
Yazeed Sawalha
Phase 1/2B

View all 14 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →